10-Q: HeartCore Enterprises Reports Q1 2024 Results Amid Shifting Revenue Landscape

Sentiment:

Quarterly Report


HeartCore Enterprises, Inc. reported a net loss of $1.48 million in Q1 2024, compared to a net income of $1.81 million in the same period last year, primarily due to decreased revenues from GO IPO consulting services.

Worse than expectedThe company reported a significant revenue decline of 42.2% in Q1 2024 compared to Q1 2023.The company reported a net loss of $1,478,002 in Q1 2024, compared to a net income of $1,808,037 in Q1 2023.Gross profit decreased by 63.9% in Q1 2024.

Summary

  • HeartCore Enterprises, Inc. reported a 42.2% decrease in total revenues, dropping to $5,046,732 in Q1 2024 from $8,734,150 in Q1 2023.
  • The revenue decline is mainly attributed to a $4,617,270 decrease in GO IPO consulting services, as two IPO consulting customers successfully listed on Nasdaq in Q1 2023, offset by a $721,815 increase in on-premise software sales.
  • The company reported a net loss of $1,478,002 in Q1 2024, compared to a net income of $1,808,037 in Q1 2023.
  • Gross profit decreased by 63.9% to $2,032,189 in Q1 2024, down from $5,633,084 in the same period last year.
  • Selling expenses decreased by 61.4% to $219,707, primarily due to a reduction in stock-based compensation.
  • General and administrative expenses decreased by 10.4% to $2,406,303, mainly due to lower stock-based compensation, offset by increased salaries and office expenses.
  • Research and development expenses slightly increased by 11.9% to $89,134.
  • The company experienced a net loss in other income (expenses), primarily due to changes in the fair value of investments.
  • Cash and cash equivalents stood at $1,219,251 as of March 31, 2024, compared to $1,012,479 at the end of 2023.

Sentiment

Score: 3

Explanation: The significant revenue decline, net loss, accumulated deficit, and Nasdaq noncompliance notice contribute to a negative sentiment. While there are some positives, such as new service agreements and a potential dividend, the overall financial performance and outlook are concerning.

Positives

  • On-premise software sales increased by $721,815 in Q1 2024 compared to Q1 2023.
  • The company secured new service agreements with Koei Shoji, PharmaBio, and Jyo to assist them in their IPO processes.
  • The company received a $5,000,000 advance payment for the sale of warrants.
  • The company declared a cash dividend of $0.02 per share.
  • The company has been granted an extension until October 21, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Negatives

  • Total revenues decreased significantly by 42.2% in Q1 2024 compared to Q1 2023.
  • The company reported a net loss of $1,478,002 in Q1 2024.
  • Gross profit decreased by 63.9% in Q1 2024.
  • The company has an accumulated deficit of $16,096,819.
  • The company is not in compliance with Nasdaq's minimum bid price requirement.
  • Other income (expenses) showed a net loss of $875,214 in Q1 2024.

Risks

  • The company is not in compliance with Nasdaq's minimum bid price requirement and may face delisting if it fails to regain compliance.
  • The company's revenue is heavily reliant on a few key customers and the GO IPO consulting business, which may fluctuate.
  • The company's GO IPO consulting business is subject to the successful listing of its clients, which is not guaranteed.
  • The company's investments in warrants are subject to market volatility and may result in losses.
  • The company faces competition in the software development and consulting industries.
  • The company's future success depends on its ability to attract and retain key personnel.
  • The company's international operations expose it to currency exchange rate fluctuations and other risks associated with doing business abroad.

Future Outlook

The company may issue quarterly dividends going forward, contingent upon the financial results. The four potential annual dividends may be equal to or greater than the April 2024 dividend.

Management Comments

  • The company is currently monitoring the closing bid price of its common stock and evaluating its alternatives, if appropriate, to resolve the deficiency and regain compliance with Minimum Bid Price Requirement.

Industry Context

HeartCore operates in the software development and consulting industries, with a focus on customer experience management and digital transformation. The company's GO IPO consulting business targets Japanese companies seeking to list on U.S. stock exchanges. The software industry is highly competitive and subject to rapid technological change. The IPO market can be volatile and influenced by various economic and regulatory factors.

Comparison to Industry Standards

  • Compared to industry standards, HeartCore's Q1 2024 revenue decline of 42.2% is significant. For example, Salesforce, a major player in the customer experience management space, reported a revenue increase of 11% in its most recent quarter.
  • HeartCore's net loss of $1,478,002 in Q1 2024 also contrasts with the profitability of many established software companies. For instance, Adobe, another competitor in the digital experience market, reported a net income of $620 million in its latest quarter.
  • HeartCore's reliance on the GO IPO consulting business, which is subject to the successful listing of its clients, makes its revenue stream less predictable than companies with more diversified offerings. Competitors like Accenture and Deloitte offer a broader range of consulting services, reducing their dependence on any single business line.
  • HeartCore's accumulated deficit of $16,096,819 is a concern compared to the strong financial position of many industry peers. For example, ServiceNow, a provider of cloud-based workflow automation solutions, has a healthy balance sheet with significant cash reserves.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Executive OfficerNASumitaka YamamotoNANA
Chief Financial OfficerNAQizhi GaoNANA
Independent DirectorNAHeather Neville2023-11-01NA

Related Party Transactions

  • As of March 31, 2024, the Company has a due to related party balance of $256 from Sumitaka Yamamoto, the CEO and major shareholder of the Company.
  • As of March 31, 2024, the Company has a loan receivable balance of $202,922 from Heartcore Technology Inc., a company controlled by the CEO of the Company.

Stakeholder Impact

  • Shareholders: The company's financial performance may negatively impact shareholder value. The declared dividend may provide some return to shareholders.
  • Employees: The company's financial performance may impact employee morale and job security. The new service agreements could create new opportunities.
  • Customers: The company's ability to provide services to its customers may be impacted by its financial performance. The success of GO IPO consulting clients will impact the company's revenue.
  • Suppliers: The company's financial performance may impact its ability to pay suppliers on time.
  • Creditors: The company's accumulated deficit and debt obligations may raise concerns for creditors.

Next Steps

  • Monitor the closing bid price of the company's common stock and evaluate alternatives to regain compliance with Nasdaq's minimum bid price requirement.
  • Continue to provide services under the agreements with Koei Shoji, PharmaBio, and Jyo.
  • Work towards the successful listing of GO IPO consulting clients.
  • Potentially issue quarterly dividends, contingent upon financial results.

Key Dates

DateDescription
2021-07-16Execution of Share Exchange Agreement with HeartCore Japan shareholders
2022-02-24Purchase of remaining shares of HeartCore Japan, making it a wholly-owned subsidiary
2022-09-06Entry into Sigmaways Agreement to acquire 51% of Sigmaways, Inc.
2023-02-01Closing of Sigmaways acquisition
2023-08-01Approval of the 2023 Equity Incentive Plan
2023-11-17Merger agreement between HeartCore Japan and HeartCore Capital Advisors
2023-11-30Establishment of HeartCore Luvina in Vietnam
2024-01-01Completion of merger between HeartCore Japan and HeartCore Capital Advisors
2024-02-23Entry into Service Agreement with Jyo Co., Ltd.
2024-03-18Entry into Service Agreement with PharmaBio Corporation
2024-04-01Declaration of cash dividend
2024-04-11Entry into Service Agreement with Koei Shoji Co., Ltd.
2024-04-24Receipt of notice from Nasdaq regarding eligibility for an additional 180-day period to regain compliance with the minimum bid price requirement
2024-05-03Payment date for cash dividend
2024-05-14Date of the report

Keywords

Customer Experience Management, CXM Platform, Digital Transformation, DX, Robotics Process Automation, RPA, Process Mining, Task Mining, GO IPO, Initial Public Offering, Consulting Services, Software Development, On-Premise Software, SaaS, Japan, Sigmaways Acquisition

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.